Should a 45‑year‑old adult in Ontario with negative hepatitis B surface antibody (HBsAb) be vaccinated against hepatitis B?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hepatitis B Vaccination for a 45-Year-Old Without Evidence of Immunity in Ontario

Yes, this patient should absolutely receive the hepatitis B vaccine series—the Advisory Committee on Immunization Practices (ACIP) now recommends universal hepatitis B vaccination for all adults aged 19-59 years, regardless of risk factors. 1, 2

Universal Vaccination Guideline

The 2022 ACIP recommendation represents a major paradigm shift from previous risk-based approaches that resulted in suboptimal adult vaccination coverage. 1, 2 All adults aged 19-59 years should receive hepatitis B vaccination, and providers should offer vaccination without requiring patients to acknowledge specific risk factors. 2

This universal approach eliminates the need to identify or document individual risk factors, which historically created barriers to vaccination. 1

Vaccination Protocol for This Patient

Administer a standard 3-dose hepatitis B vaccine series using either Engerix-B (20 μg) or Recombivax HB (10 μg) at 0,1, and 6 months. 2

Alternative vaccine options include:

  • Heplisav-B: 2-dose series (0 and 1 month) for adults ≥18 years 2
  • PreHevbrio: 3-dose series for adults ≥18 years 2

Critical timing requirements: Maintain minimum intervals of 4 weeks between doses 1 and 2,8 weeks between doses 2 and 3, and 16 weeks between doses 1 and 3. 2

Pre-Vaccination Testing Not Required

Do not delay vaccination while awaiting serologic testing results. 2, 3 Pre-vaccination testing is not required and should not be a barrier to vaccination, especially in populations that are difficult to reach. 2

If you want to confirm the patient truly lacks immunity (rather than having waned antibody levels from prior vaccination or infection), you could order hepatitis B surface antibody (anti-HBs), hepatitis B surface antigen (HBsAg), and hepatitis B core antibody (anti-HBc) testing—but administer the first vaccine dose concomitantly with blood draw. 3

Post-Vaccination Testing

Routine post-vaccination serologic testing is NOT recommended for this patient. 2 Post-vaccination anti-HBs testing 1-2 months after series completion is only indicated for specific high-risk groups: healthcare personnel with occupational blood exposure risk, HIV-infected persons, hemodialysis patients, and other immunocompromised individuals. 2

Since this patient does not fall into these categories, simply complete the vaccine series without post-vaccination testing.

If the Series Is Interrupted

Never restart an interrupted vaccine series—simply continue where you left off, regardless of the time elapsed between doses. 2, 4 This is a common pitfall that wastes doses and delays protection. 2

Special Considerations if Testing Reveals Prior Exposure

If serologic testing shows isolated anti-HBc positivity (indicating past exposure) with negative anti-HBs, still proceed with the complete vaccine series. 3 The American College of Physicians recommends that patients with isolated anti-HBc should receive hepatitis B vaccination regardless of anti-HBs status. 3

Implementation in Ontario Primary Care

In primary care settings, providers should proactively offer hepatitis B vaccination to all adults aged 19-59 years without requiring patients to request it. 2 This shifts the responsibility of initiating vaccination consideration from the patient to the provider. 1

Consider implementing standing orders to vaccinate all adults in this age group who have not completed the series. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Hepatitis B Vaccination Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Hepatitis B Core Antibody Positive, Surface Antigen Negative Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Non-Reactive Hepatitis B Surface Antibody 20 Years Post-Vaccination

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.